Autolus Therapeutics plc American Depositary Share AUTL
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-12T15:29:36.505Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2027-03-19
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-12T15:28:14.989533795Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-12T15:26:47.803633+00:00
Autolus Therapeutics plc American Depositary Share options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 1.04 | 259.7% | 57.4% | |||
| 25Δ | 2.44 | 118.3% | 113.0% | 1.12 | 234.7% | 50.3% |
| 30Δ | 2.33 | 129.6% | 107.7% | 1.21 | 209.7% | 43.3% |
| 35Δ | 2.22 | 140.9% | 102.5% | 1.30 | 184.7% | 36.3% |
| 40Δ | 2.11 | 152.2% | 97.2% | 1.39 | 159.7% | 29.3% |
| 45Δ | 2.00 | 163.6% | 92.0% | 1.48 | 134.6% | 22.3% |
| 50Δ | 1.89 | 174.9% | 86.7% | 1.62 | 126.1% | 18.3% |
| 55Δ | 1.78 | 186.2% | 81.5% | 1.78 | 123.9% | 15.6% |
| 60Δ | 1.67 | 197.5% | 76.2% | 1.95 | 121.8% | 12.8% |
| 65Δ | 1.57 | 208.8% | 71.0% | 2.11 | 119.6% | 10.1% |
| 70Δ | 2.27 | 117.5% | 7.3% | |||
| 75Δ | ||||||
| 80Δ | ||||||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.04
- IV
- 259.7%
- B/E move
- 57.4%
25Δ
- Pseudo strike
- 2.44
- IV
- 118.3%
- B/E move
- 113.0%
- Pseudo strike
- 1.12
- IV
- 234.7%
- B/E move
- 50.3%
30Δ
- Pseudo strike
- 2.33
- IV
- 129.6%
- B/E move
- 107.7%
- Pseudo strike
- 1.21
- IV
- 209.7%
- B/E move
- 43.3%
35Δ
- Pseudo strike
- 2.22
- IV
- 140.9%
- B/E move
- 102.5%
- Pseudo strike
- 1.30
- IV
- 184.7%
- B/E move
- 36.3%
40Δ
- Pseudo strike
- 2.11
- IV
- 152.2%
- B/E move
- 97.2%
- Pseudo strike
- 1.39
- IV
- 159.7%
- B/E move
- 29.3%
45Δ
- Pseudo strike
- 2.00
- IV
- 163.6%
- B/E move
- 92.0%
- Pseudo strike
- 1.48
- IV
- 134.6%
- B/E move
- 22.3%
50Δ
- Pseudo strike
- 1.89
- IV
- 174.9%
- B/E move
- 86.7%
- Pseudo strike
- 1.62
- IV
- 126.1%
- B/E move
- 18.3%
55Δ
- Pseudo strike
- 1.78
- IV
- 186.2%
- B/E move
- 81.5%
- Pseudo strike
- 1.78
- IV
- 123.9%
- B/E move
- 15.6%
60Δ
- Pseudo strike
- 1.67
- IV
- 197.5%
- B/E move
- 76.2%
- Pseudo strike
- 1.95
- IV
- 121.8%
- B/E move
- 12.8%
65Δ
- Pseudo strike
- 1.57
- IV
- 208.8%
- B/E move
- 71.0%
- Pseudo strike
- 2.11
- IV
- 119.6%
- B/E move
- 10.1%
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 2.27
- IV
- 117.5%
- B/E move
- 7.3%
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
Options history
No recorded observations
Biotechnology
AVBP
ArriVent BioPharma, Inc. (AVBP) is a dynamic biopharmaceutical company dedicated to developing pioneering therapies that address critical unmet needs in oncology and autoimmune…
More →AVIR
Description unavailable
More →AVLN
Avalyn Pharma Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for severe respiratory diseases, with its lead candidate, AV-101,…
More →AVTX
Description unavailable
More →AVXL
Anavex Life Sciences Corp. The company is headquartered in New York, New York.
More →AXSM
Axsome Therapeutics, Inc., a biopharmaceutical company, is dedicated to developing new therapies for central nervous system (CNS) disorders in the United States. The company is…
More →